Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louise Fearfield

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinical and Experimental Dermatology|June 21, 2022
Athena Speciality Certificate Examination case for formulation and systemic therapyKhawar Hussain, Louise Fearfield, Nerys Roberts
Journal of Cutaneous Pathology|May 26, 2018
Eruptive poromatosis in a patient with breast cancerTien Ming Lim, Justin Weir, Louise Fearfield
The American Journal of Dermatopathology|January 3, 2019
BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 CasesEugene Liat Hui Ong, Rishika Sinha, Shilan Jmor, et al.
The British Journal of Dermatology|October 30, 2023
How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approachAnusuya Kawsar, Khawar Hussain, Andrew James Muinonen-Martin, et al.
The Australasian Journal of Dermatology|July 3, 2021
Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanomaAarthy K Uthayakumar, Emily Rudd, Mariana Noy, et al.
Breast Cancer Research and Treatment|March 8, 2021
Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experienceSumir Chawla, Alison Hill, Louise Fearfield, et al.
British Journal of Haematology|October 9, 2003
Granulomatous slack skin disease--disease features and response to pentostatinNnenna Osuji, Louise Fearfield, Estella Matutes, et al.
The British Journal of Dermatology|August 17, 2022
Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational studyAnusuya Kawsar, Charlotte Edwards, Pooja Patel, et al.
The Oncologist|October 30, 2025
UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinomaSyed Hussain, Aisling Carr, Simon John Crabb, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical and Experimental Dermatology|June 21, 2022
Athena Speciality Certificate Examination case for formulation and systemic therapyKhawar Hussain, Louise Fearfield, Nerys Roberts
Journal of Cutaneous Pathology|May 26, 2018
Eruptive poromatosis in a patient with breast cancerTien Ming Lim, Justin Weir, Louise Fearfield
The American Journal of Dermatopathology|January 3, 2019
BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 CasesEugene Liat Hui Ong, Rishika Sinha, Shilan Jmor, et al.
The British Journal of Dermatology|October 30, 2023
How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approachAnusuya Kawsar, Khawar Hussain, Andrew James Muinonen-Martin, et al.
The Australasian Journal of Dermatology|July 3, 2021
Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanomaAarthy K Uthayakumar, Emily Rudd, Mariana Noy, et al.
Breast Cancer Research and Treatment|March 8, 2021
Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experienceSumir Chawla, Alison Hill, Louise Fearfield, et al.
British Journal of Haematology|October 9, 2003
Granulomatous slack skin disease--disease features and response to pentostatinNnenna Osuji, Louise Fearfield, Estella Matutes, et al.
The British Journal of Dermatology|August 17, 2022
Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational studyAnusuya Kawsar, Charlotte Edwards, Pooja Patel, et al.
The Oncologist|October 30, 2025
UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinomaSyed Hussain, Aisling Carr, Simon John Crabb, et al.
Pageof 1